Abstract
Malignant gliomas, the most common malignant primary brain tumors, have a deleterious clinical prognosis of approximately 12 months in unselected series. The resistance against antineoplastic therapy is apparently not only associated with a high proliferative potential, marked antiapoptotic resistance and high migratory capacity. Effective mechanisms to escape the immune response of the organism and an intense neoangiogenesis also contribute to the aggressive growth of these neoplasms. In addition to a number of molecular mechanisms, the group of glycohydrate-binding galectins seems to contribute to the aggressive growth of malignant gliomas. Galectin-1, -3, -4 and -8 have been shown to be overexpressed in malignant gliomas. Galectin-1 is known to be involved in glioma cell migration and possibly also in proliferation. In this review, various aspects of glioma biology and their therapeutic relevance is discussed. The role of galectins in apoptosis-resistance, immune response and angiogenesis is discussed and explained why these molecules are interesting targets of glioma therapy.
Keywords: Galectin, glioma, glioblastoma, therapy, angiogenesis, apoptosis, immune response, brain tumors, antineoplastic therapy, antiapoptotic resistance, apoptosis-resistance, glioma therapy
Current Pharmaceutical Biotechnology
Title:Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options
Volume: 13 Issue: 11
Author(s): Herwig M. Strik, Malgorzata Kolodziej, Wolfgang Oertel and Jorg Basecke
Affiliation:
Keywords: Galectin, glioma, glioblastoma, therapy, angiogenesis, apoptosis, immune response, brain tumors, antineoplastic therapy, antiapoptotic resistance, apoptosis-resistance, glioma therapy
Abstract: Malignant gliomas, the most common malignant primary brain tumors, have a deleterious clinical prognosis of approximately 12 months in unselected series. The resistance against antineoplastic therapy is apparently not only associated with a high proliferative potential, marked antiapoptotic resistance and high migratory capacity. Effective mechanisms to escape the immune response of the organism and an intense neoangiogenesis also contribute to the aggressive growth of these neoplasms. In addition to a number of molecular mechanisms, the group of glycohydrate-binding galectins seems to contribute to the aggressive growth of malignant gliomas. Galectin-1, -3, -4 and -8 have been shown to be overexpressed in malignant gliomas. Galectin-1 is known to be involved in glioma cell migration and possibly also in proliferation. In this review, various aspects of glioma biology and their therapeutic relevance is discussed. The role of galectins in apoptosis-resistance, immune response and angiogenesis is discussed and explained why these molecules are interesting targets of glioma therapy.
Export Options
About this article
Cite this article as:
M. Strik Herwig, Kolodziej Malgorzata, Oertel Wolfgang and Basecke Jorg, Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options, Current Pharmaceutical Biotechnology 2012; 13 (11) . https://dx.doi.org/10.2174/138920112802502051
DOI https://dx.doi.org/10.2174/138920112802502051 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics
Current Cancer Therapy Reviews Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies Opiates as Antidepressants
Current Pharmaceutical Design Drug Delivery Across the Blood-Brain Barrier
Current Nanoscience Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Effects of Brain IKKβ Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model
CNS & Neurological Disorders - Drug Targets Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets
Current Genomics Gold Nanoparticles as Carrier(s) for Drug Targeting and Imaging
Pharmaceutical Nanotechnology Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet Our Editorial Board Member
Current Pharmacogenomics and Personalized Medicine Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets